Show item record

dc.contributor.authorHuang, Kenneth
dc.contributor.authorBoisvert, Marie-Pierre
dc.contributor.authorChung, Famane
dc.contributor.authorLoignon, Maude
dc.contributor.authorZarowny, Don
dc.contributor.authorCyr, Lise
dc.contributor.authorToma, Emil
dc.contributor.authorBernard, Nicole
dc.date.accessioned2007-01-05T21:56:54Z
dc.date.available2007-01-05T21:56:54Z
dc.date.issued2006
dc.identifier.urihttp://www.jibtherapies.com/content/4/1/7
dc.identifier.urihttp://hdl.handle.net/1866/689
dc.format.extent747272 bytes
dc.format.mimetypeapplication/pdf
dc.rightsCeci est un article en accès libre diffusé sous une licence Creative Commons Paternité laquelle permet une libre utilisation, diffusion et reproduction de l'article sous toutes formes, à la condition de l'attribuer à l'auteur en citant son nom. This is an open access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.rights.urihttp://creativecommons.org/licenses/by/2.0
dc.titleLongitudinal changes in HIV-specific IFN-? secretion in subjects who received Remune™ vaccination prior to treatment interruption
dc.typeArticle
dc.contributor.affiliationUniversité de Montréal. Faculté de médecine. Département de microbiologie, infectiologie et immunologiefr
dc.identifier.doi10.1186/1476-8518-4-7
dcterms.abstractBACKGROUND:Despite the benefits of highly active antitretroviral therapy (HAART) for suppressing viral replication in HIV infection, virus persists and rebounds during treatment interruption (TI). This study explored whether HAART intensification with Remune™ vaccination before TI can boost HIV-1-specific immunity, leading to improved control of viremia off HAART.METHODS:Ten chronically HIV-infected adults were enrolled in this proof of concept study. After a 6-month HAART intensification phase with didanosine, hydroxyurea, granulocyte-macrophage colony-stimulating factor, (GM-CSF), and a first dose of Remune™ (HIV-1 Immunogen), HAART was discontinued. Patients continued to receive Remune™ every 3 months until the end of study. HAART was restarted if viral load did not fall below 50,000 copies/ml of plasma within 3 months or if CD4+ counts decreased to <200 cells/mm3. HIV-specific immunity was monitored with the interferon-? (IFN-?) ELISPOT assay.RESULTS:All subjects experienced viral rebound during TIs. Although the magnitude and breadth of HIV-specific responses to HLA-restricted optimal peptide panels and Gag p55 peptide pools increased and viral load decreased by 0.44 log10 units from TI#1 to TI#2, no significant correlations between these parameters were observed. The patients spent 50.4% of their 36 months follow up off HAART.CONCLUSION:Stopping HAART in this vaccinated population induced immune responses that persisted after therapy was restarted. Induction of HIV-specific immunity beyond IFN-? secretion may be contributing to better control of viremia during subsequent TIs allowing for long periods off HAART.en
dcterms.descriptionAffiliation: Maude Loignon, Lise Cyr & Emil Toma : Département de microbiologie et immunologie, Faculté de médecine, Université de Montréal
dcterms.isPartOfurn:ISSN:1476-8518
UdeM.VersionRioxxVersion acceptée / Accepted Manuscript
oaire.citationTitleJournal of immune based therapies and vaccines
oaire.citationVolume4
oaire.citationIssue1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show item record

Ceci est un article en accès libre diffusé sous une licence Creative Commons Paternité laquelle permet une libre utilisation, diffusion et reproduction de l'article sous toutes formes, à la condition de l'attribuer à l'auteur en citant son nom. This is an open access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Usage rights : Ceci est un article en accès libre diffusé sous une licence Creative Commons Paternité laquelle permet une libre utilisation, diffusion et reproduction de l'article sous toutes formes, à la condition de l'attribuer à l'auteur en citant son nom. This is an open access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.